content_image/200027.jpg content_image/200028.jpg
Science) utilizing most appropriate human resources (Best Talent) to engage in dynamic research activities in optimal environments (Best Place). 

In October 2013, we created Astellas Innovation Management (AIM) to expand our use of external cutting- edge science. Previously, multiple divisions separately explored external innovation opportunities of the preclini- cal stage. These functions have been integrated into AIM. AIM is working closely with each research unit to system- atically secure innovation opportunities of a broad range from bio-ventures and academia. 

## Developing New Therapeutic Areas and a Novel Technology Platform 

Under the new research framework, we aim to capture more opportunities for new drug discovery, by allocating resources more flexibly, while still valuing the strategy of selection and concentration we have pursued to date. In addition to our focus therapeutic areas, we plan to allocate 

<img src='content_image/200027.jpg'>

resources to new disease areas and drug discovery  platform technologies, while exploring potential uses of external resources. As part of this approach, we con- cluded a number of alliances with bio-ventures and other partners during fiscal 2013. We also established a special unit dedicated to accelerating our initiatives in regenera- tive medicine and embarked on full-scale research into cell therapies. 

## Aiming to Provide New Value 

Centered on the innovative new drug business, we have begun looking at ways of delivering new value to patients besides targeting new therapeutic areas. We make col- laborative efforts across varied fields such as surgery and preventive care. We have established a special unit inside Astellas and are implementing specific measures to develop new business opportunities in fields outside of therapeutic agents, leveraging the strengths we have built up in our innovative pharmaceutical business. 

<img src='content_image/200028.jpg'>

